Results 51 to 60 of about 285,624 (259)

Age-related macular degeneration: current treatments [PDF]

, 2009
Jean Pierre Hubschman, Shantan Reddy, Steven D SchwartzJules Stein Eye Institute, Department of Ophthalmology, University of California, David Geffen School of Medicine, Los Angeles, California, USAPurpose: Although important progress has been made in ...
Jean Pierre Hubschman, Steven D Schwartz, Reddy, Shantan, Shantan Reddy, Schwartz, Steven D, Hubschman, Jean Pierre   +5 more
core   +1 more source

Upadacitinib Restrains the Pathogenic Fitness of CD4+ T Cells and Aberrant B Cell Programming in Optic Neuritis

Advanced Science, EarlyView.
Single‐cell profiling and functional perturbation reveal coordinated JAK1‐pSTAT3 downstream programs in optic neuritis, including MCL1‐dependent fitness of pathogenic CD4+ Tem cells and glycolysis‐linked, cholesterol‐sensitive B‐cell responses associated with RORA. Upadacitinib disrupts this reciprocal T‐B‐cell circuit and alleviates neuroinflammation,
Gengchen Jiang, Qi Jiang, Lian Han, Yue Peng, Xingyu Liu, Tong Yang, Hao Huang, Jiaying Liu, Yuan Gao, Hui Yang, Wenjun Zou, Zhaohuai Li, Wenru Su   +12 more
wiley   +1 more source

Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment. [PDF]

PLoS ONE, 2014
Intravitreal injections of anti-vascular endothelial growth factor agents, such as ranibizumab, have significantly improved the management of neovascular age-related macular degeneration. This study used patient-level simulation modelling to estimate the
Paul Mitchell, Neil Bressler, Quan V Doan, Chantal Dolan, Alberto Ferreira, Aaron Osborne, Elena Rochtchina, Mark Danese, Shoshana Colman, Tien Y Wong   +9 more
doaj   +1 more source

The Safety of Anti-VEGF Treatment, in the Context of the Retinal Nerve Fibre Layer, in Patients with Wet Age-Related Macular Degeneration: A Review

Frontiers in Bioscience-Landmark, 2023
Anti-vascular endothelial growth factor (VEGF) drugs are widely used in modern ophthalmology, especially in treating macular disorders like age-related macular degeneration or diabetic macular edema.
Małgorzata Wichrowska, Ewa Goździewska, Jarosław Kocięcki   +2 more
doaj   +1 more source

Coagulation-balance gene predictors influencing visual prognosis in patients treated with photodynamic therapy for classic choroidal neovascularization secondary to age-related macular degeneration. [PDF]

, 2010
PURPOSE: To determine whether different coagulation-balance genetic polymorphisms explain the variable clinical outcomes of photodynamic therapy with verteporfin (PDT-V) in Caucasian patients with classic or predominantly classic choroidal ...
Romano, Mario
core  

Patient and Family Reported Clinical Picture of IRF2BPL‐Related Disorders

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, EarlyView.
ABSTRACT IRF2BPL‐related disorder is a neurodevelopmental disorder caused by heterozygous variants in the IRF2BPL (Interferon Regulatory Factor 2 Binding Protein‐Like) gene. The few reports available in the literature suggest that common symptoms include developmental delay, intellectual disability, and developmental regression.
Zoe Goldstone‐Joubert, Danielle M. Pascual, Laurie Anne Bailey, Loren D. M. Peña, Paul C. Marcogliese   +4 more
wiley   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

MFGE8 does not influence chorio-retinal homeostasis or choroidal neovascularization in vivo [PDF]

, 2012
Purpose: Milk fat globule-epidermal growth factor-factor VIII (MFGE8) is necessary for diurnal outer segment phagocytosis and promotes VEGF-dependent neovascularization.
David-Alexandre Tregouet (4350982), Florian Sennlaub (64439), Xavier Guillonneau, William Raoul (64427), Sophie Krumeich (177422), Sophie Krumeich, Raoul William, Théry Clotilde, Calippe Bertrand, Salomon-Yves Cohen, Poupel Lucie, Camelo, Serge, Xavier Guillonneau (64430), Bertrand Calippe, Behar-Cohen Francine, Tregouet, David-Alexandre, Baatz, Holger, Bertrand Calippe (177425), Florian Sennlaub, Lucie Poupel, Francine Behar-Cohen, Théry, Clotilde, Sophie Lavalette (64428), Serge Camelo (177419), Calippe, Bertrand, Cohen Salomon-Yves, Lavalette Sophie, Behar-Cohen, Francine, Clotilde Théry (177438), Lavalette, Sophie, Tregouet David-Alexandre, Christophe Combadière, Combadière Christophe, Raoul, William, William Raoul, Sennlaub Florian, Salomon-Yves Cohen (177429), Baatz Holger, Guillonneau, Xavier, Nicole Keller, Keller, Nicole, Guillonneau Xavier, Camelo Serge, Nicole Keller (64429), Keller Nicole, Cohen, Salomon-Yves, David-Alexandre Tregouet, Serge Camelo, Sophie Lavalette, Holger Baatz (177431), Krumeich Sophie, Christophe Combadière (177434), Sennlaub, Florian, Combadière, Christophe, Poupel, Lucie, Krumeich, Sophie, Lucie Poupel (177410), Holger Baatz, Clotilde Théry, Francine Behar-Cohen (64434), Behar-Cohen, F., Krumeich, S., Camelo, S., Combadière, C., Guillonneau, X., Baatz, H., Sennlaub, F., Calippe, B., Poupel, L., Théry, C., Keller, N., Lavalette, S., Cohen, S.Y., Tregouet, D.A., Raoul, W.   +74 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source